What is the best pre-therapeutic dosimetry for successful radioiodine therapy of multifocal autonomy?

NuklearMedizin

Volumn 45, Issue 5, 2006, Pages 206-212

  Gorthordt, Martin ^a,b   Rubner, C ^b   Bauhofer, A ^b   Berce, F ^b   Oyen, W J G ^a   Goecke, J ^b   Pfestroff, A ^b   Schlieck, A ^b   Corstens, F H ^a   Behe M ^b   Behr, T M ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

131I; Dosimetry; Endocrinology; Radioiodine treatment; Thyroid

Indexed keywords

IODINE 123;

ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DOSIMETRY; HALF LIFE TIME; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; RADIATION DOSE; STATISTICAL ANALYSIS; THYROID WEIGHT;

EID: 33750439851     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625221     Document Type: Article

References (28)

1. Berding G, Schicha H. Ergebnisse der Radiojodtherapie der manifesten Hyperthyreose und der autonomen Struma mit Euthyreose. Nucl Med 1990; 29: 158-65.
2. Bogner L, Czempiel H. Näherungsfehler bei der physikalischen Planung der Radiojodtherapie der Schilddrüse. Nuklearmedizin 1993; 32: 236-46.
3. Brunn J, Bloch U, Ruf G et al. Volumetrie der Schilddrüsenlappen mittels Real-Time-Sonography. D Med W 1981; 106: 1338-40.
4. Dietlein M, Dressler J, Eschner W et al. Deutsche Gesellschaft fur Nuklear Medizin; Deutsche Gesellschaft fur Medizinische Physik. Verfahrensanweisung zum Radiojodtest (Version 2). Nuklearmedizin 2003; 42: 123-5.
5. Dietlein M, Dressler J, Grünwald F et al. Leitlinien zur Radiojodtherapie benigner Schilddrüsenerkrankungen (Version 3). Nuklearmedizin. 2004; 43: 217-20.
6. Dunkelmann S, Endlicher D, Prillwitz A et al. Results of TcTUs-optimized radioiodine therapy in multifocal and disseminated autonomy. Nuklearmedizin 1999; 38: 131-9.
7. Empfehlung der Strahlenschutzkommission, "Ambulante, fraktionierte Radioiodtherapie" (suggestions of the German commitee for radiation protection, "out-patient fractionated radioiodine therapy"), Bundesanzeiger 132, 18.7. 1996.
8. Emrich D, Erlenmaier U, Pohl M et al. Determination of the autonomously functioning volume of the thyroid. Eur J Nucl Med 1993; 20: 410-4.
9. Gotthardt M, Nowak M, Béhé MP et al. Negative correlation between therapeutic success in radioiodine therapy and TcTUs: are TcTUs adapted dose concepts the only possible answer? Eur J Nucl Med Mol Imag 2003; 30: 1165-8.
10. 99mTc-uptake in autonomous thyroid tissue in Germany since the 1970s: clinical implications for radioiodine therapy. Nuklearmedizin 2006, in press.
11. Heinis J, Pfestroff A, Goecke J et al. How reliable is the correlation between TcTUs and ITUs? Eur J Nucl Med Mol Imag 2004; 31 (suppl 2): S464.
12. http://www.cebm.net/levels_of_evidence.asp (last checked May 18, 2006)
13. http://www.eanm.org/scientific_info/guidelines/guidelines_intro.php? navId=54&PHPSES-SID=87a4ba43fbf9ecac0284b3aed3cec6f4 (last checked May 18, 2006)
14. Huysmans DA, Hermus AR, Corstens FH et al. Long-term results of two schedules of radioiodine treatment for toxic multinodular goitre. Eur J Nucl Med 1993; 20: 1056-62.
15. Jarløv AE, Hegedüs L, Kristensen LØ et al. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol 1995; 43: 325-9.
16. Joseph K, Mahlstedt J, Pries HH et al. Early diagnosis and evaluation of the risk to develop hyperthyroidism in patients with autonomously functioning thyroid tissue. Nuc Compact 1977; 8: 134-9.
17. Marinelli LD, Quimby EH, Hine GJ. Dosage determination with radioactive isotopes. Practical considerations in therapy and protection. Am J Roentgenol, Radium Ther Nucl Med 1948; 59: 260-81.
18. 131Iodine. J Nucl Med 2002; 43: 856-61.
19. Meller J, Wisheu S, Munzel U et al. Radioiodine therapy for Plummer's disease based on the thyroid uptake of technetium-99m pertechnetate. Eur J Nucl Med 2000; 27: 1286-91.
20. Nüchel C, Boddenberg B, Schicha H. The value of the radioiodine uptake test for the calculation of therapeutic doses for benign thyroid disorders. Nuklearmedizin 1993; 32: 91-8.
21. Reinartz P, Zimny M, Schaefer W et al. Radioiodine therapy in patients with hyperthyroid disorders: standard versus dosimetric activity application. Nucl Med Com 2003; 24: 1247-53.
22. Reiners C, Schneider P. Radioiodine therapy of thyroid autonomy. Eur J Nucl Med 2002; 29 (suppl): S471-8.
23. Reinhardt M, Emrich D, Krause T et al. Improved dose concept for radioiodine therapy of multifocal and disseminated functional thyroid autonomy. Eur J Endocrinol 1995; 132: 550-6.
24. 99mTc-pertechnetate thyroid uptake. Eur J Nucl Med Mol Imaging 2002; 29: 480-5.
25. Richtlinie Strahlenschutz in der Medizin. GMBI 1992; 40: 991.
26. Schneider P, Körber C, Körber-Hafner N et al. Does an individual estimation of half-life improve the results of radioiodine therapy in Graves' disease? Nucl Med 2002; 41: 240-4.
27. Shapiro B. Optimization of radioiodine therapy of thyrotoxicosis: what have we learned after 50 years? J Nucl Med 1993; 34: 1638-41.
28. Yusuf S, Cairns JA, Camm AJ et al. Evidence-Based Cardiology. London: BMJ Publishing Group 1998.